Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

Abstract Background Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkp...

ver descrição completa

Detalhes bibliográficos

Principais autores:	M. Fishman, J. P. Dutcher, J. I. Clark, A. Alva, G. P. Miletello, B. Curti, Neeraj Agarwal, R. Hauke, K. M. Mahoney, H. Moon, J. Treisman, S. S. Tykodi, G. Daniels, M. A. Morse, M. K. K. Wong, H. Kaufman, N. Gregory, D. F. McDermott
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2019-03-01
Colecção:	Journal for ImmunoTherapy of Cancer
Assuntos:	Survival Risk factors Interleukin-2 Renal cell cancer PROCLAIMSM Patient registry
Acesso em linha:	http://link.springer.com/article/10.1186/s40425-019-0567-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!